Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 randomized study of TLK286 (Telcyta) [canfosfamide; Telik] versus Doxil/Caelyx [doxorubicin liposomal] or Hycamtin as third-line therapy in platinum refractory or resistant ovarian cancer [ASSIST-1 (Assessment of Survival in Solid Tumors-1)]

Next Previous
X
Search
Trial Profile

Phase 3 randomized study of TLK286 (Telcyta) [canfosfamide; Telik] versus Doxil/Caelyx [doxorubicin liposomal] or Hycamtin as third-line therapy in platinum refractory or resistant ovarian cancer [ASSIST-1 (Assessment of Survival in Solid Tumors-1)]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canfosfamide (Primary) ; Doxorubicin liposomal; Topotecan
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASSIST-1

    • Most Recent Events

    • 22 Jul 2011 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Results published in the European Journal of Cancer.
    • 14 Jan 2008 Status change from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top